Aura Biosciences: 4 of 5 low-grade NMIBC patients achieve clinical complete response with single-dose bel-sar

Aura Biosciences, Inc.

Phase 1 trial of bel-sar in NMIBC: 4 of 5 low-grade patients had complete response (no tumor cells on histopathology).
2 of 3 high-grade patients showed visual tumor shrinkage on cystoscopy; immune activation observed in all evaluable patients.
Safety: only Grade 1 drug-related AEs in <10% of patients; no serious adverse events reported as of Sept 9, 2024 cutoff.
Evidence of bladder urothelial field effect in non-target tumors, suggesting broader immune response.
Company plans to expand Phase 1 and prepare for Phase 2 trial to evaluate durability of response.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.